News Release
Oct 8, 2019
Sawai Pharmaceutical Co., Ltd.
Upsher-Smith Laboratories, LLC

UPSHER-SMITH LAUNCHES TOSYMRA™(SUMATRIPTAN) NASAL SPRAY FOR THE
ACUTE TREATMENT OF MIGRAINE IN ADULTS
Maple Grove, MN – Oct 2, 2019 – Upsher-Smith Laboratories, LLC (“Upsher-Smith”, President
and CEO: Rusty Field), a subsidiary of Sawai Pharmaceutical Co., Ltd. (“Sawai”, Head office:Osaka, Japan, President: Mitsuo Sawai) today announced the launch of Tosymra™ (sumatriptan)
Nasal Spray, 10 mg for the acute treatment of migraine with or without aura in adults. Tosymra is afast-acting, easy-to-use acute migraine treatment option that delivers the efficacy of an injectable ina convenient nasal spray.
Tosymra™, which was approved by the U.S. Food and Drug Administration in early 2019, wasrecently acquired by Upsher-Smith from Dr. Reddy’s Laboratories Limited in a strategic effort toexpand and diversify the Company’s migraine portfolio.
“We’re excited to launch Tosymra™, the third product in Upsher-Smith’s growing migraine portfolio,
which includes Qudexy® XR and Zembrace® SymTouch®,” said Rusty Field, President and CEO,Upsher-Smith. “Many patients face challenges during migraine attacks that make available acutetreatment options inadequate. Tosymra™ Nasal Spray offers an alternative to patients whose
symptoms interfere with taking oral medication or who may be dissatisfied with their current
treatment regimen.”
More than 36 million patients suffer from migraines and surveys have shown that a majority arewilling to try other acute treatment options.1 Patients currently using oral treatment options may facechallenges including nausea and gastroparesis or vomiting which may delay or limit oral medication
absorption.
1.

Bigal M, Rapoport A, Aurora S, Sheftell F, Tepper S, Dahlof C., Satisfaction with Current Migraine Therapy:Experience From 2 Centers in US and Sweden. Headache. 2007 Apr; 47(4):475-9.
https://doi.org/10.1111/j.1526-4610.2007.00752.x

About Intravail®
Intravail® is a registered trademark of Neurelis, Inc. Intravail® drug delivery technology enables thenon-invasive delivery of a broad range of protein, peptide and non-peptide drugs (up to 30,000daltons in size) that can currently only be administered by injection. Intravail® can be utilized via theoral, buccal, dermal, and intranasal routes of drug administration.
About Upsher-Smith
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve
the health and lives of patients through an unwavering commitment to high-quality products andsustainable growth. Since 1919, it has brought generics and brands to a wide array of customers
backed by an attentive level of service, strong industry relationships, and dedication toNews Release
uninterrupted supply.
As Upsher-Smith celebrates its 100-year anniversary, the company enters a new ambitious era
that has been accelerated by its 2017 acquisition by Sawai. Upsher-Smith and Sawai plan toleverage each other for growth worldwide and embark on an exciting new chapter as they seek todeliver the best value for their stakeholders, and most importantly, Do More Good™ for the patients
they serve. For more information, visit https://www.upsher-smith.com.
Qudexy, Zembrace SymTouch, Tosymra and Do More Good are trademarks of Upsher-SmithLaboratories, LLC.

◆ Contact information ◆PR / IR Group, Corporate Strategy Department, Sawai Pharmaceutical Co., Ltd.
E-mail: koho@sawai.co.jp